|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM231376138 |
| 003 |
DE-627 |
| 005 |
20250216002021.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.09.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0771.xml
|
| 035 |
|
|
|a (DE-627)NLM231376138
|
| 035 |
|
|
|a (NLM)24090708
|
| 035 |
|
|
|a (PII)S1521-6616(13)00234-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Schloot, Nanette C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a DiaPep277® and immune intervention for treatment of type 1 diabetes
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.2013
|
| 500 |
|
|
|a Date Revised 05.11.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2013.
|
| 520 |
|
|
|a Type 1 diabetes is a chronic immune-mediated disease resulting in destruction of insulin-producing β-cells. Several studies have been performed aiming to halt disease progression after diagnosis; to reduce the increased diabetes risk in islet-autoantibody positive subjects; and to prevent the onset of β-cell autoimmunity in subjects genetically at risk but without autoantibodies. Whereas secondary prevention trials failed, trials in newly diagnosed patients have shown partial success in preserving C-peptide. These studies target T-cells and inflammation and make use of antigen-specific immune modulation or stem cell approaches. However, thus far no immune-based therapeutic regimen has cured type 1 diabetes after its clinical onset or has stabilized the decline of C-peptide to achieve the status of an approved drug. This review summarizes immune intervention trials and the current knowledge of DiaPep277® peptide as a form of immune intervention in type 1 diabetes
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a C-peptide
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a T cells
|
| 650 |
|
4 |
|a Type 1 diabetes
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a C-Peptide
|2 NLM
|
| 650 |
|
7 |
|a Chaperonin 60
|2 NLM
|
| 650 |
|
7 |
|a DiaPep 277
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 700 |
1 |
|
|a Cohen, Irun R
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 3 vom: 15. Dez., Seite 307-16
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:3
|g day:15
|g month:12
|g pages:307-16
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.09.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 3
|b 15
|c 12
|h 307-16
|